肺癌与表皮生长因子受体抑制剂相关皮肤不良反应的研究热点与趋势的文献计量学分析

Bibliometric analysis of research hotspots and frontier trends in skin adverse reactions caused by epidermal growth factor receptor inhibitors in the treatment of lung cancer

目的:探讨肺癌与表皮生长因子受体抑制剂(epidermal growth factor receptor inhibitors,EGFRIs)相关皮肤不良反应的研究热点与趋势。方法:运用CiteSpace软件对自建库以来至2023年10月30日收录在中国知网、万方、维普3个数据库中有关肺癌及EGFRIs相关皮肤不良反应研究领域的文献,从年发文量、基金项目、期刊、作者、关键词等方面进行可视化分析。结果:共纳入中文文献663篇,国家级基金资助项目占比9.20%;共涉及312本期刊,发文量最多是《中国肺癌杂志》,占比2.71%;中日友好医院和北京中医药大学为发文量前2的研究机构,存在着紧密的合作关系;发文量排名前3的作者分别为崔慧娟18篇,彭艳梅11篇,张旭9篇。研究热点集中于EGFRIs相关性皮疹、吉非替尼、临床疗效;前沿趋势关注于EGFRIs类药物引起皮肤不良反应的临床观察、研究进展以及中医药等。结论:肺癌与EGFRIs相关皮肤不良反应研究的发展前景良好,发文作者与机构间可进一步形成更强有力的合作网络,促进多学科交流,共同推进该领域的研究发展。

Objective:To analyze the research hotspots and frontier trends in skin adverse reactions caused by epidermal growth factor receptor inhibitors(EGFRIs)in the treatment of lung cancer.Methods:CiteSpace software was used to visually analyze the literature on skin adverse reactions caused by EGFRIs in the treatment of lung cancer in the three databases of CNKI,WANFANG and VIP from the establishment of the database to October 30,2023.The literature was analyzed from the aspects of annual publication volume,funding,journals,authors,keywords,etc.Results:A total of 663 Chinese literature were obtained,with national funding projects accounting for 9.20%.A total of 312 journals were involved,with the highest publication volume being the Chinese Journal of Lung Cancer,accounting for 2.71%.The China-Japan Friendship Hospital and the Beijing University of Chinese Medicine were the top two research institutions in terms of the number of published papers,and they had a close cooperation relationship.The top three authors in terms of publication volume were CUI Huijuan with 18 articles,PENG Yanmei with 11 articles,and ZHANG Xu with 9 articles.Research hotspots focus on EGFRIs related rash,gefitinib,and clinical efficacy.Frontier trends focused on the clinical observation,research progress,and traditional Chinese medicine of skin adverse reactions caused by EGFRIs drugs.Conclusions:The research on skin adverse reactions caused by EGFRIs in the treatment of lung cancer has great development prospects.Authors and institutions can further form a stronger collaborative network to promote interdisciplinary communication,and jointly promote research and development in this field.